Shanghai Pharmaceuticals Holding Co Ltd - Company Profile
Powered by 
All the data and insights you need on Shanghai Pharmaceuticals Holding Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Shanghai Pharmaceuticals Holding Co Ltd Strategy Report
- Understand Shanghai Pharmaceuticals Holding Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Shanghai Pharmaceuticals Holding Co Ltd (Shanghai Pharma) manufactures, markets, and distributes healthcare products. The company produces pharmaceutical products for the treatment of diarrhea, jaundice, fever, iron deficiency anemia, pancreatitis, coronary heart disease, lupus erythematosus, leprosy, acute myocardial infarction, and other diseases. It offers medicines for diseases and disorders of the cardiovascular system, digestive and metabolic system, neurological system, musculoskeletal system, and respiratory system. Shanghai Pharma also provides traditional Chinese medicines. It provides retail, distribution, and supply chain solutions to pharmaceutical manufacturers and dispensers; and operates retail and chain pharmacies. The company operates in China through its subsidiaries. Shanghai Pharma is headquartered in Shanghai, China.
Headquarters
China
Address
Shanghai Pharmaceutical Mansion, No.200 Taicang Road, 200020
Website
www.sphchina.com/index
Telephone
86 21 63730908
No of Employees
48,164
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
601607 (SHA)
Revenue (2022)
$36.8B
12.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-32.9%
(2022 vs 2021)
Market Cap*
$7.7B
Net Profit Margin (2022)
XYZ
-40.1%
(2022 vs 2021)
* As of and is in US$
Shanghai Pharmaceuticals Holding Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceutical Products | Retail Services | Sine |
| Traditional Chinese Medicines | Production Services | Lei’s |
| Chemical Drugs | Distribution Services | Dragon & Tiger |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company and Wing Fat Printing entered into the procurement framework agreement, under which Wing Fat Group will provide printed packaging materials for pharmaceutical products to the Group. |
| 2022 | Contracts/Agreements | In November, Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd and Ogalon (Shanghai) Pharmaceutical Trading Co., Ltd signed a letter of intent for the "New Retail Broad Market Project. |
| 2022 | Contracts/Agreements | In November, Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. and Takeda China signed a commercial strategic cooperation to carry out all-round cooperation in product innovation, supply chain services and marketing across the country. |
Competitor Comparison
| Key Parameters | Shanghai Pharmaceuticals Holding Co Ltd | China National Accord Medicines Corporation Ltd | Nanjing Pharmaceutical Co Ltd | Elion Energy Co Ltd | Tasly Pharmaceutical Group Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Shenzhen | Nanjing | Beijing | Tianjin |
| State/Province | Shanghai | Guangdong | Jiangsu | Beijing | Tianjin |
| No. of Employees | 48,164 | 39,296 | 5,058 | 3,880 | 9,183 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zhou Jun | Chairman | Executive Board | 2019 | 54 |
| Shen Bo | Chief Financial Officer; Director; Vice President | Executive Board | 2019 | 50 |
| Cho Man | Executive Director; President | Executive Board | 2019 | 62 |
| Zuo Min | Director; President | Executive Board | - | 62 |
| Li Yongzhong | Executive Director; Vice President | Executive Board | 2019 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward